LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

1.37 -2.84

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.3599999999999999

Max

1.43

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
EPS	-0.37
Peļņas marža	-176.706
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+368.09% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	6.7M 102M
Iepriekšējā atvēršanas cena	4.21
Iepriekšējā slēgšanas cena	1.37

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. dec. 22:13 UTC

Peļņas

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025. g. 9. dec. 21:40 UTC

Peļņas

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025. g. 9. dec. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025. g. 9. dec. 16:57 UTC

Galvenie tirgus virzītāji

Clear Secure Rises on Medicare Identity Verification Contract

2025. g. 9. dec. 23:46 UTC

Tirgus saruna

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025. g. 9. dec. 23:46 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings Stake in Lenovo Now at 32.34%

2025. g. 9. dec. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025. g. 9. dec. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025. g. 9. dec. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025. g. 9. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025. g. 9. dec. 22:42 UTC

Peļņas

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 21:48 UTC

Tirgus saruna

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025. g. 9. dec. 21:36 UTC

Peļņas

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025. g. 9. dec. 20:28 UTC

Tirgus saruna

Oil Futures Decline for Second Straight Session -- Market Talk

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025. g. 9. dec. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Teck Reports Voting Results From Special Meeting of Hldrs

2025. g. 9. dec. 20:26 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025. g. 9. dec. 20:21 UTC

Tirgus saruna

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025. g. 9. dec. 19:52 UTC

Peļņas

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025. g. 9. dec. 19:17 UTC

Peļņas

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025. g. 9. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. dec. 17:11 UTC

Peļņas

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

368.09% augšup

Prognoze 12 mēnešiem

Vidējais 6.6 USD 368.09%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.